HK1076711A1 - Chimeric cd154 - Google Patents

Chimeric cd154

Info

Publication number
HK1076711A1
HK1076711A1 HK05107749.4A HK05107749A HK1076711A1 HK 1076711 A1 HK1076711 A1 HK 1076711A1 HK 05107749 A HK05107749 A HK 05107749A HK 1076711 A1 HK1076711 A1 HK 1076711A1
Authority
HK
Hong Kong
Prior art keywords
chimeric
human
sequence encoding
vector
polynucleotide sequence
Prior art date
Application number
HK05107749.4A
Other languages
English (en)
Inventor
Charles E Prussak
Thomas J Kipps
Mark J Cantwell
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of HK1076711A1 publication Critical patent/HK1076711A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Detergent Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polyoxymethylene Polymers And Polymers With Carbon-To-Carbon Bonds (AREA)
HK05107749.4A 2002-05-23 2005-09-02 Chimeric cd154 HK1076711A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/154,759 US7495090B2 (en) 2002-05-23 2002-05-23 Nucleic acids encoding chimeric CD154 polypeptides
PCT/US2003/016305 WO2003099340A1 (fr) 2002-05-23 2003-05-23 Nouveau ligand chimere appele cd154

Publications (1)

Publication Number Publication Date
HK1076711A1 true HK1076711A1 (en) 2006-01-27

Family

ID=29548954

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05107749.4A HK1076711A1 (en) 2002-05-23 2005-09-02 Chimeric cd154

Country Status (14)

Country Link
US (3) US7495090B2 (fr)
EP (1) EP1509253B1 (fr)
JP (1) JP4454493B2 (fr)
CN (1) CN100482283C (fr)
AT (1) ATE458058T1 (fr)
AU (1) AU2003231819B2 (fr)
CA (1) CA2486918C (fr)
DE (1) DE60331307D1 (fr)
DK (1) DK1509253T3 (fr)
ES (1) ES2341331T3 (fr)
HK (1) HK1076711A1 (fr)
IL (1) IL165347A (fr)
PT (1) PT1509253E (fr)
WO (1) WO2003099340A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
US7786282B2 (en) * 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US7495090B2 (en) * 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
EP2066339B1 (fr) * 2006-09-18 2014-08-13 The Board Of Trustees Of The University Of Arkansas Compositions et procédés pour améliorer des réponses immunes
JP2010511731A (ja) * 2006-12-05 2010-04-15 メムジェン エルエルシー キメラｉｓｆ３５を利用した化学療法剤に対する癌感受性増強方法
US9125854B2 (en) * 2007-10-30 2015-09-08 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
EP3097926B1 (fr) 2007-11-01 2019-10-02 The Board of Trustees of the University of Arkansas Compositions et procédés pour amplifier des réponses immunitaires à l'eimeria
JP6242050B2 (ja) 2010-01-21 2017-12-06 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 免疫応答を増強するワクチンベクターおよび方法
KR101881611B1 (ko) 2010-06-09 2018-07-25 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 캄필로박터 감염을 감소시키기 위한 백신 및 방법
EP3421487B1 (fr) 2010-10-19 2023-06-28 The Regents of the University of Colorado, a body corporate Peptides permettant de moduler l'activité des lymphocytes t et leurs utilisations
WO2014132142A2 (fr) * 2013-01-30 2014-09-04 King Abdullah University Of Science And Technology Procédé de séparation de cellules adhérentes pour cytométrie en flux
ES2968398T3 (es) 2013-02-14 2024-05-09 Univ Arkansas Composiciones y métodos para potenciar las respuestas inmunitarias a Eimeria o limitar la infección por Eimeria
EP3578190A1 (fr) 2013-03-15 2019-12-11 The Board of Trustees of the University of Arkansas Compositions et procédés pour améliorer les réactions immunitaires aux pathogènes entériques
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CN114920840A (zh) 2014-10-14 2022-08-19 诺华股份有限公司 针对pd-l1的抗体分子及其用途
EP3878465A1 (fr) 2015-07-29 2021-09-15 Novartis AG Polythérapies comprenant des molécules d'anticorps tim-3
EP3964528A1 (fr) 2015-07-29 2022-03-09 Novartis AG Polythérapies comprenant des molécules d'anticorps dirigées contre lag-3
EA201890434A1 (ru) 2015-08-05 2018-10-31 Янссен Байотек, Инк. Антитела к cd154 и способы их применения
WO2017079297A1 (fr) 2015-11-02 2017-05-11 Memgen Llc Méthodes pour le traitement d'un cancer
WO2017079202A1 (fr) 2015-11-02 2017-05-11 Board Of Regents, The University Of Texas System Méthodes d'activation de cd40 et blocage de points de contrôle immunitaires
AU2016369537B2 (en) 2015-12-17 2024-03-14 Novartis Ag Antibody molecules to PD-1 and uses thereof
AR108688A1 (es) 2016-05-03 2018-09-19 Univ Arkansas Vector de vacuna de levadura que incluye polipéptidos inmunoestimuladores y antigénicos, métodos para su uso
US11298420B2 (en) 2016-12-21 2022-04-12 Memgen, Llc Armed oncolytic viruses
EP3565578A1 (fr) 2016-12-21 2019-11-13 Memgen LLC Adénovirus oncolytiques armés aptes à la réplication
WO2018191369A1 (fr) * 2017-04-12 2018-10-18 Memgen, Llc Procédés d'activation immunitaire de récepteur de type cd40 et toll
MX2020007081A (es) * 2018-01-05 2020-10-28 Op T Llc Peptidos terapeuticos y metodos para tratar enfermedad relacionada con la autoinmunidad.
AU2019288277A1 (en) * 2018-06-19 2021-01-28 H. Lee Moffitt Cancer Center And Research Institute, Inc. Oncolytic virus or antigen presenting cell mediated cancer therapy using type I interferon and CD40-ligand
MX2021010831A (es) 2019-03-08 2021-12-15 Obsidian Therapeutics Inc Composiciones de ligando del cumulo de diferenciación 40 (cd40l) y métodos para regulación ajustable.
US11793854B2 (en) 2019-03-21 2023-10-24 Op-T Llc Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction
AU2020290522A1 (en) 2019-06-12 2022-01-20 Obsidian Therapeutics, Inc. CA2 compositions and methods for tunable regulation
CN116390749A (zh) * 2020-09-11 2023-07-04 曼珍公司 使用嵌合cd40配体和冠状病毒疫苗增强免疫力
WO2022060904A1 (fr) 2020-09-16 2022-03-24 Obsidian Therapeutics, Inc. Compositions et procédés pour l'expression de récepteurs de lymphocytes t avec cd40l régulé par petites molécules dans les lymphocytes t

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002A (en) * 1841-03-12 Tor and planter for plowing
US22017A (en) * 1858-11-09 Pen-fountain
US5095096A (en) 1987-05-29 1992-03-10 Sagami Chemical Research Center Fused protein comprising lymphotoxin
JP2930713B2 (ja) 1989-08-16 1999-08-03 カイロン コーポレイション タンパク質ホルモン形成の抑制用の組成物およびその使用法
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
ES2198025T3 (es) 1991-10-25 2004-01-16 Immunex Corporation Anticuerpos contra cd40-l.
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
WO1994004680A1 (fr) 1992-08-21 1994-03-03 Schering Corporation Interleukine-13 humaine
CA2153806C (fr) 1993-01-22 2005-11-08 Melanie K. Spriggs Detection et traitement des mutations dans un gene ligand cd40
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5861310A (en) 1993-11-03 1999-01-19 Dana-Farber Cancer Institute Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
JPH08127594A (ja) 1993-11-10 1996-05-21 Mochida Pharmaceut Co Ltd Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ
AU1059095A (en) 1993-11-24 1995-06-13 Australian National University, The Treatment of viral disease with cd40l peptide
DE69535719T2 (de) 1994-01-07 2009-03-19 Mochida Pharmaceutical Co. Ltd. Fas-antigenbindender ligand
MX9605088A (es) 1994-04-28 1997-08-30 Boehringer Ingelheim Pharma Metodos para proliferar y diferenciar celulas b y sus usos.
US5759536A (en) 1994-05-27 1998-06-02 University Technology Corporation Use of fas ligand to supress T-lymphocyte-mediated immune responses
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
US5888764A (en) 1995-01-20 1999-03-30 Uab Research Foundation Human fas gene promoter region
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
DE69841548D1 (de) 1997-09-17 2010-04-22 Mochida Pharm Co Ltd Fas-liganden derivate
US6451759B1 (en) 1998-01-14 2002-09-17 The Regents Of The University Of California Noncleavable Fas ligand
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
US20020022017A1 (en) 2000-04-12 2002-02-21 Hua Yu Regulation of systemic immune responses utilizing soluble CD40
US7495090B2 (en) * 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
GB2392158B (en) 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof

Also Published As

Publication number Publication date
WO2003099340A1 (fr) 2003-12-04
ES2341331T3 (es) 2010-06-18
DK1509253T3 (da) 2010-06-07
IL165347A (en) 2012-05-31
CN100482283C (zh) 2009-04-29
US7928213B2 (en) 2011-04-19
AU2003231819A1 (en) 2003-12-12
EP1509253B1 (fr) 2010-02-17
AU2003231819B2 (en) 2008-07-10
CA2486918A1 (fr) 2003-12-04
JP4454493B2 (ja) 2010-04-21
DE60331307D1 (de) 2010-04-01
ATE458058T1 (de) 2010-03-15
IL165347A0 (en) 2006-01-15
PT1509253E (pt) 2010-05-21
US20100297695A1 (en) 2010-11-25
EP1509253A4 (fr) 2005-12-21
US8138310B2 (en) 2012-03-20
EP1509253A1 (fr) 2005-03-02
CN1671423A (zh) 2005-09-21
US7495090B2 (en) 2009-02-24
JP2005537785A (ja) 2005-12-15
US20110177556A1 (en) 2011-07-21
CA2486918C (fr) 2013-08-27
US20030220473A1 (en) 2003-11-27

Similar Documents

Publication Publication Date Title
HK1076711A1 (en) Chimeric cd154
WO2002095014A3 (fr) Polypeptides presentant une activite de cellobiase et polynucleotides codant pour de tels polypeptides
PT1240325E (pt) Polipéptidos homólogos de il-17 e il-17r e suas utilizações terapêuticas
IL161769A0 (en) Anbtimicrobial polypeptides from pseudoplectania nigrella
ATE352626T1 (de) Polypeptide mit galaktoseoxidaseaktivität und dafür kodierende nukleisäuren
UA97946C2 (ru) Моноклональное антитело, специфически связывающееся с внеклеточным доменом ilt7 человека
WO2005069762A8 (fr) Chromosome du bacillus licheniformis
AU2003291962A1 (en) Polypeptides having cellobiohydrolase ii activity and polynucleotides encoding same
DK1131444T3 (da) Polypeptider med lysophospholipase aktivitet og nucleinsyre som koder for disse
DK1165759T3 (da) Polypeptider, der har forgrenende enzymaktivitet, og nukleinsyrer, der koder for samme
MX2022008955A (es) Variantes de mananasas y polinucleotidos que las codifican.
DK0981631T3 (da) Polypeptider, som har aminopeptidase-aktivitet, og nukleinsyrer, som koder for samme
DK1756273T3 (da) Signalpeptid til frembringelse af et polypeptid
NO20085086L (no) Fettsyresyntetase, polynukleotid som koder denne og anvendelse derav
NO940655L (no) N-Acetylglukosamintransferase V kodende sekvenser
EP0972054A4 (fr) Amelioration de la reaction immune au moyen de molecules de ciblage
KR100717353B1 (ko) 피키아 파스토리스 유래의 자동 유도성 ｎｐｓ 프로모터 및이를 이용한 이종 단백질의 제조방법
WO2005021578A3 (fr) Nouveau polypeptide chimere et son utilisation
GR3037092T3 (en) Tyrosinase-activator protein fusion enzyme
EP1572133A4 (fr) Methode d'identification de modulateurs du recepteur de l'orexine 2 humain
MX2023001888A (es) Variantes de una xiloglucanasa de la familia 44.
Wittenbrink et al. Differential NKG2D binding to highly related human NKG2D ligands ULBP2 and RAET1G is determined by a single amino acid in the α2 domain
DK1226236T3 (da) Polypeptider, der har glucanotransferase-aktivitet, og nucleinsyrer, som koder disse
TW200517399A (en) A novel chimeric polypeptide and use thereof
AU2002304915A1 (en) Cation conducting gabaa receptors and their use

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20230518